Loading clinical trials...
Loading clinical trials...
Risdiplam - A Phase I, Open-Label, Multi-Period Crossover Study to Investigate the Safety, Food Effect, Bioavailability and Bioequivalence of Oral Doses of Two Different Formulations in Healthy Subjects
Conditions
Interventions
risdiplam
omeprazole
Locations
4
United States
Daytona Beach Clinical Rsch Unit
Daytona Beach, Florida, United States
QPS- Springfield
Springfield, Missouri, United States
Dallas Clinical Research Unit
Dallas, Texas, United States
Covance Clinical Research Unit, Inc
Madison, Wisconsin, United States
Start Date
February 1, 2021
Primary Completion Date
January 28, 2023
Completion Date
January 28, 2023
Last Updated
March 13, 2023
NCT05808764
NCT05861986
NCT05755451
NCT05618379
NCT02908685
NCT04674618
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions